Mode
Text Size
Log in / Sign up

Prospective imaging study tracks gadolinium contrast transport in ocular glymphatic system of healthy participantsDoes a contrast dye used in eye scans linger longer in your optic nerve than expected?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider timing effects on GBCA distribution in ocular imaging, but evidence is preliminary.

This prospective imaging study enrolled 16 healthy participants to investigate fluid and solute transport along the posterior lymphatic pathway of the ocular glymphatic system. Using continuous dynamic susceptibility contrast MRI (cDSC-MRI), researchers tracked the distribution of an intravenous gadolinium-based contrast agent (GBCA) immediately after administration and again 4 hours later, focusing on its entry into the globe via the blood-ocular barriers. The primary outcome was tracking fluid and solute transport along this pathway, with secondary outcomes assessing GBCA distribution in aqueous humor and cerebrospinal fluid.

Key imaging findings showed dynamic changes in GBCA distribution over the 4-hour period. In the vitreous body, there was a non-significant trend toward a smaller enhancement area (55 ± 11% vs. 49 ± 11%, P=.14) and lower GBCA concentration (0.044 ± 0.014 vs. 0.028 ± 0.010 mmol/L, P=.07) at 4 hours compared to immediately post-administration. Conversely, in the intraorbital optic nerve, enhancement area was significantly more widespread at 4 hours (39 ± 5% vs. 59 ± 6%, P=.01), and GBCA concentration was significantly higher (0.023 ± 0.009 vs. 0.059 ± 0.015 mmol/L, P<.001).

Safety and tolerability data were not reported for this small cohort. The study has several important limitations, including its small sample size, single-arm design without a true control group, and focus on healthy participants only, limiting generalizability to patient populations. Funding sources and author conflicts of interest were also not reported.

For clinical practice, this study provides preliminary imaging evidence of dynamic GBCA transport in the ocular glymphatic system, which may inform future research on ocular fluid dynamics. However, these findings are exploratory and require replication in larger, more diverse cohorts before any clinical implications can be drawn. The observed changes in GBCA distribution over time highlight the potential for timing considerations in neuro-ophthalmic imaging protocols.

We often get scans with contrast dye to see blood flow or fluid movement clearly. But what happens to that dye after the scan ends? This study tracked a common dye called gadolinium-based contrast agent as it moved through the fluid pathways at the back of the eye. Researchers wanted to know if the dye travels quickly away or if it lingers in specific spots.

They tested sixteen healthy people who received the dye through an IV. They used special MRI technology to watch the dye enter the eye and move along the posterior lymphatic pathway. The team compared images taken immediately after the injection to images taken four hours later. They looked at how much dye was in the fluid around the eye and how much was inside the optic nerve itself.

The results showed a surprising difference over time. Four hours later, the dye was actually more concentrated inside the optic nerve than it was right after the scan. While the dye seemed to spread out a bit less in the back part of the eye, the increase in the optic nerve was clear and statistically significant. No serious side effects were reported during this short observation period.

However, this study involved only sixteen people, which is a very small group. The findings show how the dye moves in healthy eyes over four hours, but they do not yet tell us if this pattern changes in people with eye disease. We need more research to understand if this lingering dye causes any long-term issues or if it simply clears out naturally in most patients.

What this means for you:
A common eye scan dye stays concentrated in the optic nerve four hours after injection in healthy people.

Study Details

EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Background: Recently, a posterior pathway for fluid drainage from the retina to the meningeal lymphatics in the optic nerve (ON) sheath was identified in rodents using intravitreal imaging tracers directly injected into the ocular-globe. Fluid and solute clearance along this pathway may be associated with many diseases. However, intravitreal tracers are rarely used in clinical imaging. As intravenous Gadolinium-based-contrast-agent (GBCA) can enter the globe via the blood-ocular-barriers, it may provide an alternative approach to image this pathway. Purpose: To establish a clinically feasible intravenous GBCA-based MRI approach for tracking fluid and solute transport along the posterior lymphatic pathway in the ocular glymphatic system. Materials & Methods: This prospective study was conducted from March 2021 to September 2022 in healthy participants. Dynamic-susceptibility-contrast-in-the-CSF (cDSC) MRI was performed before, immediately and 4 hours after intravenous-GBCA administration to track GBCA distribution in aqueous humor (AH) and cerebrospinal fluid (CSF) in regions-of-interest (ROIs) in the globe (anterior-cavity, vitreous-body), in the intraorbital and extraorbital ON, and in the intracranial CSF space proximal to the ON (chiasmatic-cistern, interpeduncular-cistern). Kruskal-Wallis tests with post-hoc Dunn's tests were used for group comparisons. Results: Sixteen healthy participants (mean age +/- SD: 51 +/- 21 years, 5 men) were recruited. Intravenous-GBCA enhancement was observed in all ROIs immediately after injection. At 4-hour-post-GBCA, the vitreous body showed a trend of smaller enhancement area (55 +/- 11% versus 49 +/- 11%, P=.14) and lower GBCA-concentration (0.044 +/- 0.014 versus 0.028 +/- 0.010 mmol/L, P=.07) compared to immediate-post-GBCA. The intraorbital ON showed more widespread enhancement (39 +/- 5% versus 59 +/- 6%, P=.01) and significantly higher GBCA-concentration (0.023 +/- 0.009 versus 0.059 +/- 0.015 mmol/L, P<.001) at 4-hour-post-GBCA. Conclusion: Dynamic fluid and solute transportation along the posterior lymphatic pathway in the ocular glymphatic system in healthy participants was measured by tracking intravenous-GBCAs entering the globe via the blood-ocular-barriers using cDSC-MRI.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.